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SUMMARY Changes in histamine storage in the oxyntic mucosa of duodenal ulcer patients and
their reversal by vagotomy and the histamine H2-antagonist cimetidine supported the hypothesis
that histamine could be a causal factor in peptic ulcer pathogenesis. The specificity of these
findings was impaired by problems in biopsy taking, however, and in the preparative steps before
measuring the actual histamine contents in all parts of the gastric mucosa and in the duodenum.
A prospective trial was carried out in 190 patients to identify these sources of bias and to
overcome them by appropriate study designs.1 Usually a direct correlation was found between
weight of biopsy and mucosal histamine content. This problem was solved by selecting a biopsy
forceps producing smaller variations in sample size, by limiting the time of cold ischaemia to four
to five minutes only and by taking three biopsy specimens for each single histamine value.2 The
actual histamine content of mucosal biopsies remained constant for about four to five minutes
only. The 'disappearance' rate was faster in control subjects than in duodenal ulcer patients.
Hence by variation of the cold ischaemia time any artefacts of differences between mucosal
histamine levels in controls and duodenal ulcer patients could be produced.3 Using the optimised
sample taking procedure mucosal histamine contents of several gastric regions and the duodenal
bulb were measured in 24 patients with duodenal ulcer, after selective proximal vagotomy
without drainage and in control subjects without any stomach disease (randomised controlled
trial). The histamine content was lower in all parts of the upper gastrointestinal tract in duodenal
ulcer patients than in controls and was raised again in all regions after selective proximal
vagotomy. As the most likely hypothesis it is suggested that vagal reflexes with'afferent fibres
coming from the oxyntic mucosa stimulate histamine release in duodenal ulcer patients by
efferent peptidergic neurones to all parts of the stomach and the duodenum where the ulcer
lesion is situated.
A series of congruous findings in the last decadel-8 compared with those subjects with normal clinical
supports the hypothesis that histamine is a causal and endoscopical findings in stomach and duode-
factor (contributory condition or even sufficient num. These alterations are reversed in patients after
determinant9) in duodenal ulcer pathogenesis. Fun- adequate selective vagotomy2 10 and cimetidine
dic6 and corpus' 5 mucosal histamine content and treatment5 but not in those with Hollander-
histamine methyltransferase activity3 6 7 9 1( are de- incomplete vagotomy2 and with recurrent ulceration
creased in patients with chronic duodenal ulcer as both after gastric and selective proximal vago-
tomy.2 5 "0 The mucosal histamine content after
selective vagotomy and pyloroplasty is inversely
Address for correspondence: Klaus Thon, MD, surgical Clinic, Centre of correlated to the residual peak acid output andOperative Medicine I, Philipps-University of Marburg, Boldingerstrasse, 3550 corltd te rsdalpa3cdotu n
Marburg (Lahn), Federal Republic ofGermany. directly proportional to its reduction.3
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factor in peptic ulcer disease, however, specificity of
all these changes and associations is a vital criterion
which has many dimensions. Most of which are not
investigated thoroughly enough or even are a matter
of considerable debate because histamine is only
one candidate among so many active substances"
which are claimed to be involved in peptic ulcer
disease. The criteria include (a) specificity of the
fluorometric and radio-enzymatic assays in most
common gastric diseases and after medical treat-
ment,2 3 7 12-15 (b) that of sample taking3 16-8 and
of the reference systems (wet weight, tissue protein
and DNA), (c) specificity with regard to the
patient's attributes (age, sex, additional genetic and
environmental factors, smoking, alcohol and
drugs'-7 19 20) and the status of health and disease
(return of the values to 'normal' after healing the
ulcer), (d) specificity of the alterations with regard
to the topographical distribution (oxyntic mucosa,
duodenum) and finally (e) the specificity of inter-
preting the decrease of mucosal histamine une-
quivocally as histamine release. 2 3 8 15 21
Two of these problems in specificity are the
subject of this communication: sample taking and
regional distribution. Preliminary reports were
given at the European Gastro Club 2 and the
German Surgical Society.23
Methods
MATERIALS
This series of prospective trials was carried out in
190 German patients of the Surgical Clinic, Mar-
burg/Lahn from 1973 to 1983 by five endoscopists,
two technicians and one coordinator who remained
throughout. The seven series of the study were
conducted with relatively long lasting intervals as we
became only gradually aware of the numerous
problems associated with sample taking of mucosal
biopsies-.2 3 1648 The attributes of the patients were
compiled in detail in Table 1 except those from 126
subjects from whom only the frequency distributions
of biopsy weights were reported (Fig. 1).
Biopsy specimens were removed from all the
patients in study who had fasted overnight, during
routine endoscopy from 0830 am-1200 noon. A
panendoscope 7089 P (ACMI, WaVpler, Munich)
was used in the first 136 subjects, an Olympus
endoscope GIF-Q with the 'hot biopsy' forceps
FD-12 in the remaining 54 patients.
As soon as the final diagnosis was established by
clinical and endoscopical findings four to 11 speci-
mens were withdrawn from the middle of the corpus
region at the greater curvature.16 During stepwise
biopsy taking, however, in the controlled clinical
trial (no 7) additionally four mucosal specimens
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Fig. 1 Frequencv distributions of biopsy weights obtained
with two different types of biopsy forceps. Single values
obtainedfrom three specimens ofan individual patient. A
few samples were lost (seven in series a, two in series b). In
the two trials only two endoscopists were involved in sample
taking. For further conditions see Materials and Methods.
were removed from the fundus (paracardially at the
greater curvature), from the antrum (2-5 cm orally
from the pylorus again at the greater curvature) and
from the duodenum (middle of the bulb at the lesser
curvature). From each gastric region one biopsy was
used for microscopical examination.
The mucosal specimens were placed on hard filter
paper (Whateman No 2) in a petri dish which was
moistened with a few drops of Ringer solution, were
weighed on an analytical microbalance (Sartorius
type 2774 in 1973, and then Mettler, type H-20 T)
within no more than five minutes after withdrawal
or after defined points of time in the corresponding
experiments and were each suspended in 2 ml 1 M
HC104. These mixtures were kept at -20°C in a
deep freezer for no longer than two weeks before
histamine determination.
The same drugs and reagents for histamine assay
were used as described by Rohde et al.'6 Usually,
however, no premedication was necessary in the
patients. Some of them asked for a local anaesthetic
spray (xylocaine), only three in 1983 received the
previously used premedication, 16 but all of the
subjects drank 1-2 ml SAB-Simplex®' (Parke-Davis)
in about 30 ml tap water. Most of the patients were
admitted to hospital in the precimetidine era, but
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Table 1 Details ofpatients
Patients Date of Patients Date of
No Initials Sex Age Diagn Concomitant dis endoscopy No Initials Sex Age Diagn Concomitant dis endoscopy
1 NK M 80 UV(J1) None 23.6.76 35 WA F 67 CS None 8.2.83
2 LCh F 75 CS None 7.7.76 36 BM M 51 UD Adipositas 9.2.83
3 SchE M 52 CS None 7.7.76 per-magna, Bypass
4 PA F 50 UD None 12.7.76 op, renal calc.
5 CPh M 68 UV(J1) Coronary insuff, 15.7.76 37 BP M 71 CS None 9.2.83
Diabetes, gout 38 SW M 45 SPV None 22.2.83
6 DKH M 29 CS Cholelithiasis 19.7.76 39 FH M 23 CS None 1.3.83
7 FB M 50 CS Cholelithiasis 20.7.76 40 KI F 53 UD None 16.3.83
8 EF M 55 CS Bronchial carc. 20.7.76 41 WK F 42 CS None 17.3.83
9 EE F 40 CS None 21.7.76 42 SchA F 55 UD None 22.3.83
10 PE M 46 UD None 21.7.76 43 LL M 60 UD Ca of the tongue 28.3.83
11 JJ M 71 CA None 2.8.76 44 BH M 50 SPV Herniated disc 29.3.83
12 HM F 67 CS Diabetes 2.8.76 45 BK F 71 SPV None 5.4.83
13 GA F 67 UD Coronary insuff. 2.8.76 46 HH M 50 CS None 19.4.83
14 SchH M 58 CS Cytogenic epilepsy 2.8.76 47 KE M 50 SPV None 19.4.83
15 ZO M 44 CA None 6.8.76 48 HH M 40 SPV None 20.4.83
16 GS F 80 CA(BII) None 9.8.76 49 GA M 60 CS None 13.5.83
17 HK M 44 UD None 9.8.76 50 LJ M 59 CS None 5.7.83
18 WJ M 25 CS Alcoholism 9.8.76 51 EJ M 51 UD None 6.7.83
19 CS M 33 UD None 13.8.76 52 AH M 62 CS Oesophagitis II, 6.7.83
20 FK M 54 CS Cholelithiasis, 25.8.76 cholelithiasis
Hypertension 53 StM F 45 CS None 2.8.83
21 KF M 62 UV(J1) Coronary insuff. 31.8.76 54 BM F 72 CS None 3.8.83
22 KA M 63 UV(J2) None 31.8.76 55 BR M 71 UD Oesophagitis II 5.8.83
23 BV M 41 CS None 31.8.76 56 FH M 44 CS None 9.8.83
24 BF M 47 UD None 31.8.76 57 SchM F 64 UV(J1) None 9.8.83
25 ThH M 71 CS None 31.8.76 58 EK M 58 UD Obstructive vascular 10.8.83
26 DF M 59 UD None 1.2.83 disease
27 MKH M 46 SPV Cholelithiasis 2.2.83 59 MHD M 27 SPV,RUD None 15.8.83
28 ML M 64 UD None 2.2.83 60 SchK M 74 UD Adipositas 15.8.83
29 EB M 22 CS None 3.2.83 per-magna
30 KR M 38 UD Alcoholism 7.2.83 Hypertension, MI
31 LHH M 39 CS Hyperplasia papillae 7.2.83 61 ZW M 86 UD None 30.8.83
32 CS M 34 SPV None 8.2.83 62 GM F 47 UD None 31.8.83
33 JJ M 34 SPV None 8.2.83 63 KJ M 50 CS None 5.9.83
34 SchM F 59 UD None 8.2.83 64 BKH M 69 UD None 5.9.83
For allocation of patients to the various parts of this communication see study designs. Abbreviations starting from top left: M=male,
F=female, UV=gastric ulcer, Jl,2=gastric ulcer, type Johnson I and II, SPV=selective proximal vagotomy, CS=control subjects,
UD=duodenal ulcer, RUD=recurrent duodenal ulcer, CA=gastric carcinoma, (BII)=after Billroth II resection, oesophagitis II=reflux
oesophagitis, grade II according to Savrany-Miller, MI=myocardial infarction.
those in 1983 were asked to stop medical treatment
for peptic ulcer, except low doses of antacids, for
two days before endoscopy, because cimetidine and
ranitidine interfere with the histamine assays
(Lorenz, unpublished data), alter histamine storage5
and metabolism,8 and pirencepine inhibits human
gastrointestinal diamine oxidase. 24
EXPERIMENTAL DESIGNS
Relationship between weight of biopsy and
mucosal histamine content
In this part of the study four series of experiments
were conducted from 1973 to 1983.
(1) Biopsy specimens from corpus mucosa of 111
patients,' 2 three from each subject, were taken
between April and September 1973, and weighed on
a Sartorius microbalance. The dispersion of the
specimen sizes was investigated by plotting the
frequency distribution of the weights.
(2) The large variation in biopsy weights and its
influence on the depth of sample taking from the
corpus mucosa by the ACMI biopsy forceps16
induced the second series of experiments in nine
patients (nos 1-9 in Table 1) in 1976. This studied
the relationship between the weight of biopsy and its
mucosal histamine content. Eleven specimens were
taken from six control subjects with a healthy upper
gastrointestinal tract, but some of them with con-
comitant diseases influencing tissue histamine
levels25 and from three patients with peptic ulcer.
The time of cold ischaemia (from withdrawal of
mucosa by the scissors of the forceps via placing the
particles in the petri dish, transport to the weighing
room and weighing up to the fixation in 2 ml 1 M
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HC104) was exactly recorded for each of the
specimens by using a stopwatch. Mucosal histamine
concentrations were determined in 10 biopsy speci-
mens as described below and wet weight and
histamine content of each sample were correlated to
each other without correction for the time of cold
ischaemia.
(3) The results of the second series of experiments
led to a considerable search for endoscopic equip-
ment and biopsy forceps which reduced the disper-
sion of sample weights and produced on the average
larger biopsies.16 The Olympus GIF-Q instrument
which by a smaller diameter and more flexibility
reduced the number of patients needing premedica-
tion and the 'hot biopsy' forceps were finally
selected. They were used in 54 patients (Table 1) in
1983 to reinvestigate the mean value and variation
of specimen sizes by again constructing the histo-
gram of the biopsy weights. Three specimens were
analysed from each subject, a few biopsies were lost.
(4) Meanwhile the importance of cold ischaemia
time for tissue histamine levels in human subjects
was fully recognised.'8 Thus in the fourth series of
experiments in 1983 this time interval was limited to
five minutes for each biopsy specimen. The relation-
ship between weight of biopsy and mucosal hista-
mine content was reinvestigated in 15 patients, six
control subjects and nine patients with peptic ulcer,
some of them again with concomitant diseases which
may alter mucosal histamine concentrations (nos
50-60 in Table 1). Otherwise the same design was
used in this study as in the second series of
experiments.
Relationship between cold ischaemia time and
mucosal histamine content
Two series of experiments were carried out in this
part of the study from June to August 1976. They
were carefully designed to measure as accurately as
possible actual histamine levels which were defined
as those existing in the human corpus mucosa in vivo
exactly at the time of investigation and being not
significantly altered by the time after the sample
taking procedure.
(5) In the fifth trial three control subjects, three
patients with duodenal ulcer and three with gastric
carcinoma (nos 10-18 in Table 1) were recruited
from all subjects admitted to endoscopy. To imitate
a random assignment they were selected exactly in
the sequence in which patients with these three
diagnoses entered the hospital at this particular time
of the year. From each of them nine biopsy
specimens were taken for histamine assays and at
least one for histology. The time from excision of
biopsy up to its fixation in perchloric acid (cold
ischaemia time) was prolonged for each of the
samples consecutively from two minutes for the first
one up to 20 minutes for the last specimen. A
syringe needle was used to remove the biopsy from
the forceps. After weighing the needle was used
again to deposit the mucosal specimen about 0*5 cm
above the surface of 2 ml 1 M HC104, on the inner
wall of a test tube, then the biopsy was suspended in
the fixation fluid by shaking it on a whirlmix
apparatus. This technique was helpful in this series
of experiments but essential in the sixth trial, where
any contact of an instrument with the suspension
fluid had to be carefully avoided to prevent errors in
the weighing process. After withdrawal of the first
two biopsies within a 30 second interval one person
started the weighing procedure whereas another
collected the remaining seven samples in further 30
second intervals. The cold ischaemia time for each
of the biopsies (increasing by two minutes for each
sample) was exactly recorded by using a separate
stopwatch for each of the investigators.
(6) The aim of the sixth trial was to find out
whether a plateau phase existed for actual histamine
contents of human corpus mucosa after withdrawal
which was long enough to permit an accurate
estimation of stored and free histamine concentra-
tions in routine endoscopy. Free histamine in
plasma has a half-life time of about two minutes.26 If
free histamine in the interstitial space had similar
kinetics very short cold ischaemia times in the range
of five to 10 seconds should be necessary for
measuring actual histamine levels. This could be
achieved only by immediately fixing biopsies in
perchloric acid without interruption by the weighing
procedure. Without change of the reference system
- for example, protein, DNA - which introduced
new problems in data interpretation, the difficulties
could be solved only by a sophisticated gravimetric
method which guaranteed the accuracy of the biopsy
weights and avoided even 'negative' values for the
mucosal specimens which sometimes were observed.
Loss and trapping of aqueous vapour into or from
the environment, respectively, had to be minimised
and equilibrated. Endoscopy and weighing were
carried out in the same room in this study.
To prepare seven second biposies, 2 ml volumes
of 1 M HC104 were filled into five test tubes (10 ml)
with ground joint and ground glass stoppers the
technician wearing plastic gloves throughout the
experiment. One mol/litre HC104 was found to be
an eutropic solution which did not gain or lose
weight in the tubes at 20°C. After closing the tubes
for one hour to obtain a constant vapour pressure
they were opened for 10 seconds, closed again,
carefully rubbed off with weighing paper and
weighed with stoppers and fluid (approximately 20
g) on the analytical microbalance. In the following
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hour when endoscopy was carried out under routine
conditions, one person opened the tubes sequential-
ly for only about 10 seconds when the biopsy was
taken and immediately deposited in the tube by a
second person as described in series 6. Any contact
with the perchloric acid had to be absolutely
avoided. The tube was closed and the biopsy washed
into the fluid by using a whirlmix apparatus. After
closing, the tube was placed in a test tube rack until
the other four specimens were taken and processed
in the same way. Then it was rubbed off again and
weighed to calculate the weight of the biopsy (about
5-7 mg).
Two control experiments were necessary to test
the reliability of the gravimetric method. (1) The
relative accuracy of the weighing procedure was
ascertained by comparing the mean values of biopsy
weights of five seven second samples with those of
five four minute samples which were obtained by the
standard procedure described in Materials. They
should be equal within the statistical limits given by
the standard sample taking procedure. In training
experiments before this study it was proven that the
mean value of weights of at least five individual
biopsies was equal to that of five others taken before
or after them (within the statistical limits). (2) Five
test tubes were processed exactly like those with
seven second biopsies, but without actually adding
tissue specimens. The mean of their weights before
and after opening the tubes had to be equal (within
the tight statistical limits of weighing) and hence
could be used to correct the biopsy weights.
To compare the histamine contents of seven
second biopsies with those of four minute biopsies
three control subjects, two patients with duodenal
ulcer and two with gastric ulcer (nos 19-25 in Table
1) instead of those with gastric cancer (not available
at this time) were recruited from all subjects
admitted to endoscopy in the same way as in trial 5.
From each of them 10 biopsies were taken for
histamine assays, five for seven second biopsies and
five for four minute biopsies (one condition of the
experiment was carried out after the other, but the
order in each pair was obtained by randomisation
with random digits). At least one biopsy was taken
for routine histology.
Regional distribution of mucosal histamine content
In the seventh series of experiments a randomised
controlled clinical trial was conducted in 24 patients
(nos 26-49 in Table 1) including eight control
subjects (age 46 years (x), six men), eight patients
with chronic duodenal ulcer (54 years (x), five men)
and eight patients with selective proximal vagotomy
without pyloroplasty for duodenal ulcer (48 years
(x), seven men) 6-12 months after operation with-
out symptoms and endoscopical evidence for recur-
rent ulceration. The aims of the trial were (a) to
investigate mucosal histamine contents under opti-
mum sample taking conditions (test for validation of
previous findings,' 2 (b) to study mucosal histamine
concentrations in several parts of the upper gastro-
intestinal tract and especially in the duodenum as
the place of the lesion to examine the specificity of
the previous findings in the corpus mucosa' 2 and (c)
to test for the first time the influence of selective
proximal vagotomy on the mucosal autocoid con-
centration which is said to be si§nificantly involved
in normal gastric acid secretion.
The 24 patients were recruited from a current
series of 374 endoscopies in February to April 1983
by a random design using a balanced random
allocation with random digits. The selection from so
many endoscopies was carried out by awaiting the
next subject fitting to the next allocation group
demanded by the randomisation procedure. In
every subject informed consent was obtained for
taking several biopsy specimens additional to the
routine procedure. Then endoscopy was carried out
establishing the final diagnosis. If this diagnosis
fitted to that demanded in the random sequence of
allocation, 16 biopsies were taken stepwise in the
shortest possible time including four from the
fundus, four from the corpus, four from the duoden-
al bulb and four from the antrum - according to the
conditions described in materials. Two people were
necessary to determine the weight of the biopsies
within four to five minutes. Three biopsies were
taken for histamine assays, one for histology.
Histamine was determined in all samples of an
individual patient at a single run in one particular
day. Only one technician who was not informed
about the diagnosis (blind study) analysed the
specimens. Additional attributes of the patients
were assessed as described in Methods.
Histamine was determined fluorometrically by a
modified Shore28 procedure. After thawing the
single biopsy was homogenised with an Ultraturrax
homogeniser (microshaft TP 10 N) and was added to
the usual mixture of n-butanol, NaOH and NaCl in
the first steps of the extraction method without
centrifugation. Long and narrow Corning glass
tubes (Sovirel®, 18x 180 mm, 25 ml, with screw
cups) and a Heidolph shaking apparatus were used
for this and the other two solvent partition steps,
hence all centrifugations after the extractions
proved to be unnecessary. This shortened the
procedure considerably. The shaking time for suffi-
cient extraction was 20 minutes in the first, two
minutes in the second and six minutes in the third
step of the method. Histamine ended in 3 ml 0-1 M
HCl of which 2 ml were mixed with NaOH,
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o-phthaldialdehyde and HCl, as described in the
original assay,28 except that 0O1 ml 0*05%
o-phthaldialdehyde was added instead of 0*1 ml 1%
o-phthaldialdehyde to improve specificity while
keeping accuracy because only very small amounts
of tissue were used in this modification (cf. 18).
Histamine was measured in a Zeiss spectrofluoro-
meter PMQ 5 at an excitation wave length of 360 nm
and emission wave length of 450 nm against a
standard calibration curve18 and the mucosal hista-
mine content was calculated according to
Hesterberg et al'8 and expressed in ,ug histamine
dihydrochloride/g wet weight.
The recovery of histamine after extraction and
condensation was assessed both by the external and
internal standard method; 200 ng authentic hista-
mine was added to 2 ml 1 M HC104 or biopsy
homogenate. The recovery rate was found to be 78
(62-102)% in the first and 78 (65-95)% in the
second method (n=24, x (range)). Two samples of a
biopsy pool homogenate obtained from 52 patients
with various gastric diseases were added to each run
as quality controls, and the results were analysed by
the double-standard control chart method.3
Clinical diagnoses and assessment of the patient's
attributes including smoking habits, Visick grading
after vagotomy and completeness of vagotomy were
established by the same careful and extended
techniques as described previously.'"' Control sub-
jects and several groups of patients with diseases of
the upper gastrointestinal tract were defined accord-
ing to Troidl et al.1 Control subjects were healthy
with respect to stomach and duodenum.
For statistical analysis both the mean SD and
median percentile system had to be applied depend-
ing on the frequency distributions. Because biopsies
were taken several times from the same patient a
two factorial analysis of variance with a repeated
measurement design29 was conducted in the control-
led clinical trial with regional distribution of hista-
mine as factor A and status of disease (control,
duodenal ulcer, selective proximal vagotomy) as
factor B. A linear model was chosen for correlation
and regression analysis. The sample correlation
coefficient r and the regression line were calculated
by the method of least squares and Ho for r was
tested according to Snedecor and Cochrane30 using
the Hewlett-Packard desk computer 9815 A. In the
two series of experiments the nominal p-value of the
ax-error was not corrected for repeated significance
testing.
Results
RELATIONSHIPS BETWEEN BIOPSY WEIGHT AND
MUCOSAL HISTAMINE CONTENT
In contrast to accepted paradigms in histamine
research28 31 32 the mucosal histamine content was
no longer independent of the weight of a biopsy, but
correlated either directly (in most cases) or in-
directly with the other variable (Fig. 2, Table 2).
Even more important than this correlation was the
steepness of the regression lines (Fig. 2). Hence any
mucosal histamine value could be arbitrarily 'deter-
mined' depending on the size of biopsy taken in a
particular state of health and disease (mucosal
thickness etc.).
Analysing the correlation between the two vari-
ables in relation to the variation of biopsy weights
and cold ischaemia times (Table 2) as well as sex,
age and disease (Table 1) only trends could be
observed, probably due to the still relatively small
sample size. The firmest correlation was found at
the largest variation in biopsy weights including
30 Sch. E . * 30 L. Ch
r=-0-27 | r=-061 020 *20
10 . 10 .
4 8 12 4 8 12
Fig. 2 Relationship between
weight ofbiopsy and mucosal
histamine content. Histamine
values and weights as single
values obtainedfrom single
biopsy specimen. Forfurther
conditions see Table 2 and text
in Materials and Methods.
PA NK
40 r=0-85 / 30- r=-0.59
20-
20 * 10-
0 i 0 -I
4 8 12 4s
Wet weight of the biopsy (mg )
.0
8 1.
1170
Sample taking and actual histamine
Table 2 Correlation coefficients and regression lines
between weights ofbiopsies and mucosal histamine contents
(ACMI biopsy forceps)
Patient Biopsy taking Relation between weight and MHC
Weight CIT Coeff of
Nodiag (mg) (min) correlation Regression line
1 UV 80-10-5 10-15 -0-59 ns y= 36 97-2-56x
2 CS 78-10-6 12-15 -0-61 ns y= 41-14-2-97x
3 CS 64-11.3 11-12 -0-27 ns y= 30-02-1-13x
4 UD 40-12-2 11-15 0-85 (p<005) y=- 9-12+4-90x
5 UV 5-2- 8-3 10-15 O59ns y= 1-83+1 15x
6 CS 19- 9-4 15-26 0 94 (p<005) y= 4-23+6-23x
7 CS 80-11-6 11-19 0 52 ns y=-12-74+3-65x
8 CS 93-11 9 9-20 0O55 ns y=-11-77+2-51x
9 CS 6-1-10-8 10-19 O-S0 ns y= 16-24+3-02x
Weights and histamine contents obtained from single biopsies.
n= 10 per patient, weight and cold ischaemia time (CIT) are
expressed as range. Diag=diagnosis, coeff=coefficient,
MHC=mucosal histamine content. Patients 1-9-1-9 in Table 1.
For further conditions see Material and Methods. ns=not
significant.
those with the lowest absolute weights (patients no 4
and 6). In addition, sample taking with the longest
cold ischaemia time (no 6) was connected with the
firmest correlation whereas that with the shortest
time was associated with the weakest (no 3). No
trends, however, could be observed with sex, age or
disease of the patients but a multifactorial relation-
ship could not be excluded at all.
Three measures were taken, based on this analy-
sis, to control the problem of varying biopsy weights
as a rather unpredictable source of relevant bias. (a)
A biopsy forceps was selected which produced
considerably less variation in biopsy weights than
the ACMI instrument (Fig. 1). (b) The cold
ischaemia time was exactly measured for each
biopsy taken and was limited to five minutes.
Specimens undergoing a larger period were dis-
carded (Table 3). (c) The mucosal histamine content
of a single patient was always calculated as the mean
of three values obtained from different specimens
(cf. 1-3). In this way, histamine values based on
mean biopsy weights were compared which differed
from patient to patient by no more than 10%
(section 3, controlled clinical trial).
As a result of the first two measures, only three of
15 patients or 20% showed coefficients of correla-
tion r¢0*5 or r--0 5 in the validation study (Table
3) as compared with eight of 10 subjects or 80% in
the test study (Table 2). In addition, the regression
lines were steeper in the first study than in the
second one (greater coefficients in x in the regres-
sion equations), especially in the cases with larger
biopsy weight variations. It is therefore concluded
that the two factors, size of the biopsy and cold
ischaemia time, may indeed be mainly responsible
Table 3 Correlation coefficients and regression lines
between weights ofbiopsies and mucosal histamine content
(hot biopsy forceps, cold ischaemia time 5 min)
Relation between weight and MHC
Patient Biopsy weight
No Diag (mg) Coeffof correlation Regression line
1 CS 49-6-6 0-54ns y=13-14+2-27x
2 UD 44-8-4 0-36ns y=16-92+1-17x
3 CS 5-1-8-1 0-00 ns y=32-95+0-13x
4 CS 49-7-6 -0-30 ns y= 17-44-0-80x
5 CS 66-7-6 0-58 ns y=16-37+6-09x
6 UD 7-1-8-3 0-14 ns y=15-49+0-81x
7 CS 4-7-7-1 0-22 ns y=23-85+0 61x
8 UV 38-9 0 0-20 ns y=32-93+0-09x
9 UD 2-49-4 0-32 ns y= 19-78+0-56x
10 RUD 6-87-8 -0-28 ns y=40-26-2-13x
11 UD 64-7-8 0-17 ns y=17-86+5-21x
12 UD 2.74-2 -0-14 ns y=29-04-1-16x
13 UD 3-1-7-4 O-S0 ns y=21-20+1-54x
14 CS 36-9-7 -0-26 ns y=40-92-1 *OOx
15 UD 3-2-7-2 0-32 ns y= 16-32+0-73x
Weights and histamine contents obtained from single biopsies.
n= 10 per patient, biopsy weight is expressed as range. Patients
50-64 inTable 1. For further conditions see Table 2.
for the bias observed and can be satisfactorily
excluded by the measures taken in the validation
study.
RELATIONSHIP BETWEEN COLD ISCHAEMIA TIME
AND MUCOSAL HISTAMINE CONTENT
The actual histamine content of mucosal biopsies
remained constant for about four to five minutes
only and decreased stepwise by about 40% (Fig. 3)
within 20 minutes. The 'disappearance' rate de-
pended on the status of health and disease. It was
faster in control subjects than in duodenal ulcer
patients (Fig. 4) whereas patients with gastric
carcinoma showed a trend which was situated
between those of the two other groups.
Mucosal histamine contents obtained after an
extremely short ischaemia time differed from those
after four to five minutes only by about 10% (Table
4). Biopsy weights, however, also tended to be 10%
lower in specimens weighed by the gravimetric
method than in those weighed by a routine proce-
dure. As in comparisons of mean biopsy weights of 4
minute samples obtained from two consecutive sets
of five biopsy specimens from the same corpus
mucosa in the same sample taking process, the
means did not systematically differ from each other
this small difference between seven second and 4
minute biopsy weights may be a systematic error in
the one or the other sample preparation procedure.
If mucosal histamine contents were corrected for
this factor they were equal in seven second and four
minute biopsies.
1171
Thon, Lorenz, Ohmann, Weber, Rohde, and Roher
U,
.E
Fig. 3 Decrease of mucosal 00histamine contentfollowing z
sample taking as related to cold
ischaemia time. Median (range)
of nine patients (No 10-18 in
Table1). Forfurther conditions
see Materials and Methods.
0
0
0 0
0
Duodenal ulcer
n=3 x
__~ ~~____
~-0~~ 0 0 p o
Gastric carcinoma
n=3 x
o0L
0-
o 0*
10
Control subjects
nt3 X
0- I.
0 5 10 15
Time (minutes)
20
Fig. 4 Decrease ofmucosal histamine contentfollowing
sample taking as related to cold ischaemia time and the
status ofhealth and disease. Mean value ofthree individuals
in each group ofthe patients (No 10-18 in Table 1). For
further conditions see Materials and Methods.
MUCOSAL HISTAMINE CONTENT IN THE UPPER
GASTROINTESTINAL TRACT IN MAN
In a randomised controlled clinical trial mucosal
histamine concentrations were obtained from 24
patients with an optimised sample taking procedure
(Fig. 5). The medians in the eight control subjects
were 37*5 ug/g for the fundic mucosa, 30 for the
corpus, 25 5 in the antrum and 26 in the bulbus
duodeni. At first glance, the variation of histamine
values may be considered as relatively large, but
calculation of the interquartile ranges easily showed
that it was equal to that in well-designed animal
experiments. Compared with those in other
human tissues all mucosal histamine levels have to
be regarded as high tissue amine levels.8 18
In duodenal ulcer patients the mucosal histamine
Table 4 Mucosal histamine content following cold
ischaemia time of 7 seconds or 4-5 minutes
Patient 7seconds 4-5 minutes
No Diag Weight MHC Weight MHC
(mg) (pg/g) (mg) (p.g/g)
1 UD 7.8 16-5 8 5 13 5
2 CS 65 218 72 214
3 UV 7-2 18 7 84 19-5
4 UV 6-5 19-2 77 190
5 CS 6-4 225 72 225
6 UD 8-8 217 9 7 18 6
7 CS 6-8 306 7 1 29 5
Total 6-8 217 7.7 19-5
(R(range)) (6-48-8) (16-5-30-6) (7.1-9.7) (13.5-29-5)
Weights and histamine contents obtained from single biopsies.
Data are given as mean values of five estimations at 7 seconds and
4-5 minutes, diag=diagnosis, MHC=mucosal histamine content.
Patients 19-25 in Table 1. For further conditions see Materials and
Methods.
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Fig. 5 Mucosal histamine
concentrations in several gastric
regions and the duodenum of
control subjects, duodenal ulcer
patients and patients 6-12
months after selective proximal
vagotomy without pyloroplasty
for duodenal ulcer. The single
values in the figure are means
ofthree measurements with
three different biopsies. For
further conditions see Materials
and Methods. Analysis of
variance: factor A regional
distribution p<O0OJ, factor B
diseasep<O0OS.
contents were considerably lower in all regions of
the gastric mucosa and the duodenum. On the
average, the changes were -27% in the fundus,
-32% in the corpus, -36% in the antrum and
-35% in the duodenum (Fig. 5). The reduction in
corpus mucosal histamine content in duodenal ulcer
patients as compared with control subjects was also
shown in the other experimental series, such as in
patients nos 10-18 of Table 1 (-31%) (Fig. 4), in
patients 19-25 (-34%) (Table 4) and in patients
50-64 among whom the control subjects showed
29.8 ,g/g histamine in the corpus mucosa and the
duodenal ulcer patients 23.5 ,tg/g (-21%). Thus the
changes of mucosal histamine in duodenal ulcer
patients as compared with healthy controls could be
reproduced several times over a period of 10 years'
both qualitatively and quantitatively provided that
the histamine assay, sample taking and allocation of
the patients to trial were tested and shown to be
reasonably reliable.
Selective proximal vagotomy without pyloroplasty
reversed the alterations of mucosal histamine levels
in duodenal ulcer patients (Fig. 5). In the corpus
mucosa this finding confirmed the previous observa-
tions after selective vagotomy with pyloroplasty.2
Surprisingly,' however, selective proximal vagotomy
affected all parts of the upper gastrointestinal tract
in the same way despite the fact that only the
fundus-corpus areas were vagally denervated. Com-
pared with duodenal ulcer patients the increase in
mucosal histamine content was +49% in the fundus,
+66% in the corpus, +67% in the antrum and
-x- median
~~~II
O -A //4J
C,6 Rg nvf th eup e t
Rof the upper gostroinksitinal tract
+76% in the duodenum. Such dramatic changes in
tissue histamine concentrations have never been
described in man.
Peden et al7 found an association between smok-
ing and the decrease in fundic mucosal histamine
concentrations in duodenal ulcer patients which to a
large extent could explain the alterations of gastric
histamine observed in peptic ulcer. Thus smoking
habits, Visick grading and completeness of vago-
tomy (adequate vagotomy)33 were recorded and
analysed in the clinical investigation and follow up.
Smoking (at least five cigarettes/day) was recorded
in three of the control subjects but in six of the
duodenal ulcer patients supporting the findings of
Peden et al.7 After vagotomy five of the patients
stopped smoking for the first four weeks. In the
second follow up six to 12 months after vagotomy six
of eight patients were again smokers (10-40 ciga-
rettes/day). Despite this habit, the mucosal hista-
mine levels in these patients were very high (Fig. 5)
indicating an association, but no simple causal
relationship between smoking and decreased hista-
mine levels in duodenal ulcer patients.
In the eight patients after vagotomy three had
Visick I, four Visick II and one Visick III. Two
patients, one with Visick II and one with Visick III
had an incomplete (Hollander-positive and Hol-
lander-positive plus Bachrach-positive) vagotomy.
Their corpus histamine content was only 22 and 28
,ug/g, respectively supporting the hypothesis that a
complete vagotomy is necessary to raise mucosal
histamine concentrations.2
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Discussion
The putative role of active substances (paracrine,
endocrine, and neurocrine mediators and neuro-
transmitters) in the pathogenesis of duodenal ulcer
was substantiated in a series of reviews in the last
few years.11 34 4 Changes of their contents were
shown in the mucosa of the upper gastrointestinal
tract and in body fluids supplying or draining these
tissues in patients with the corresponding disease.
They include from the classical autocoids and
hormones the acetylcholine-cholinesterase system,41
histamine3 8 42 and in numerous communications
gastrin.4350 As second messengers and promoters of
consecutive steps in stimulus-secretion coupling the
adenylate cyclase system with cAMP and cGMP51-55
and ATPase were investigated. Especially in the last
six years, however, regulatory peptides such as
secretin,56 cholecystokinin,57 and in several trials
somatostatin50 5860 as usually inhibitory principles
were studied in tissues and body fluids of control
subjects and peptic ulcer patients. Finally, a large
series of clinical biochemical research was dedicated
to prostaglandins which exert a powerful protective
effect on the gastroduodenal mucosa.39 61-68
The many thoughtful hypotheses on messenger
molecules in intercellular communication69 and pep-
tic ulcer pathogenesis, however, were essentially
weakened by regularly occurring contradictory find-
ings about the changes of these active substances in
tissues and body fluids (Table 5).
We became more and more convinced1 316 (this
article) that puzzling data and mental confusion
were caused largely by insufficiencies of clinical-
biochemical trials which did not satisfactorily meet
the criteria which have to be fulfilled in such a rather
complex clinical situation. The studies must be
designed: (1) with an assay for active substance(s)
which is reliable (sensitive, specific, precise in the
long run, accurate etc.) in health and various
Table 5 Contradictory findings on levels or synthesis of
active substances in human gastric mucosa comparing
duodenal ulcer patients with healthy controls
Active Mucosal levels or synthesis in DUpatients
substances Raised Equal Decreased
Histamine Domschke (13) Peden (7) Troidl (1)
Man (5)
Gastrin Creutzfeldt (43) Hughes (46) Malmstrom(44)
(G17 and G34) Sumii (48) Barbara (47)
Sumii (50)
Somatostatin McIntosh (60) Creutzfeldt (59) Chayrialle (58)
Sumii (50)
Prostaglandin
E2 Aly (70) Schlegel (66) Konturek (67)
diseases and in clinical conditions, not only in the
laboratory. These requirements were tested for
histamine in gastric mucosal biopsies3 but unfortun-
ately they were published in detail only for preci-
3 16 7sion, not yet for specificity and accuracy.71
Enormous problems arose in demonstrating speci-
ficity, but finally it was shown that diseases and drug
treatment interfered more with the tests on specific-
ity than with the specificity of the assay itself.71
Problems with the reliability of assays for gas-
trin44 49 and prostaglandins3 68 were recognised,
but hitherto not sufficiently settled and for somato-
statin the situation seems even worse.
The studies must be designed2 with well defined
and reliable sample taking and preparation proce-
dures. Again, these requirements were tested for
histamine in great detail including weight of the
specimens (this communication), horizontal distri-
bution of histamine in the corpus mucosa,16 vertical
distribution of histamine within the mucosa,16 cold
ischaemia time (this communication), within-day
precision of sample takin 2 3 and day to day
precision of sample taking.2 3Perchloric acid extrac-
tion for free histamine was complete.28 Hence
sample taking problems were settled for histamine
but are still a matter of debate for gastrins40 48 49
and prostaglandins and are unsettled for somato-
statin.39 68 In addition, the problem of cold
ischaemia time was already strongly emphasised by
Feldberg and Schilf3l and several other groups (see
reference 3) for histamine and by Gershon37 for
serotonin. For peptide hormones and prostaglandins
it seems highly relevant but the authors have
completely neglected this problem in their com-
munications. All discrepancies between the hista-
mine studies could be explained simply by different
effects of cold ischaemia time on mucosal amine
concentrations in duodenal ulcer patients and con-
trol subjects (Fig. 6).
The studies must be designed3 as controlled
clinical trials. Active substances in the gastro-
duodenal mucosa are regulated by a vast number of
influences which are time dependent such as the
natural history and time-course of the ulcer itself
and which are defined by genetic and environmental
factors3 18 including habits of patients (smoking,
alcohol, and drugs).72 Thus any kinds of changes in
mediator concentrations can be produced in clinical
studies as artefacts if these prognostic factors are not
fairly equally distributed. Histamine, in addition, is
localised in mast cells which participate in immuno-
logical processes. Single prognostic factors have
been investigated in trials on active substances and
peptic ulcer, such as histamine,7 gastrin73 and
somatostatin.74 As yet no multivariate analysis has
been conducted and only limited consequences were
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Fig. 6 Differences in gastric mucosal histamine levels
between duodenal ulcer patients and healthy controls
obtained in several studies and explained by different
sample taking (time ofcold ischaemia). Time course
constructed from Fig. 4, differences between DUpatients
and controls (in per cent) taken from the references in Table
5. Forfurther information on Domschke's trial see Rohde et
al. 16
drawn from epidemiological findings in designing
studies on peptic ulcer pathogenesis, except for
histamine1-3 (this communication). The reason for
this regrettable situation can easily be found in this
article: hundreds of patients admitted to the endo-
scopical unit were necessary to select the rather
small number of 24 patients by strict randomisation.
We have to think about other study designs which
make reliable trials on peptic ulcer pathogenesis
more feasible.
The controlled clinical trial in this communication
confirmed the previous findings on decreased hista-
mine levels in the corpus mucosa of duodenal ulcer
patients and increased contents after vagotomy.' 2
All these changes were, however, not specific for
the acid producing part of the stomach, but occurred
in all gastric regions and in the duodenal bulb as
well. Hence these findings did not support the
previous hypothesis of an increased histamine re-
lease by an increased vagal drive2 in duodenal ulcer
disease inducing gastric hyperchlorhydria but also
did not contradict it. The uniform biochemical
changes pointed to a more general alteration in
histamine storage in this disorder than only to a
defect in the oxyntic mucosa. Several hypotheses
could be developed. (1) The alterations of histamine
content in the corpus mucosa were induced directly
by selective proximal vagotomy, in the antrum and
duodenum indirectly by inhibition of H(+)-ion
back-diffusion (partial Davenport hypothesis). (2)
The alterations of histamine content in duodenal
ulcer disease were not the cause but the conse-
quence of hyperchlorhydria and hypersecretion
followed by an increased H(+)-ion back-diffusion
(Davenport hypothesis). (3) The alterations of
histamine content were triggered by mast cell
receptors which were regulated by the intragastric
pH (effect contrary to that observed at .G-cells). (4)
The alterations of histamine content were caused by
trophic effects on mast cell proliferaiton induced by
an augmented release of gastrin following vago-
tomy. (5) Finally, an interesting new hypothesis was
developed22 23 which offered the possibility of new
relevant experiments. Vagal reflexes with afferent
fibres coming from the oxyntic mucosa stimulate
histamine release in duodenal ulcer patients by
efferent peptidergic neurons to all parts of the
stomach and especially to the duodenum where the
ulcer lesion is situated. This hypothesis could
explain the effect of selective proximal vagotomy
and seemed reasonable since substance P, neuroten-
sin and somatostatin were all shown to be potent
histamine releasers from mast cells (for review see
reference 9). In addition, the Davenport hypothesis
and to some extent also the other ones were not
supported by the recent finding that omeprazole,
the potent inhibitor of gastric ATP-ase, reduced the
peak acid output by 95%, but did not change the
corpus mucosal histamine levels20 in duodenal ulcer
patients.
This study is dedicated to Professor Horst Hamel-
mann on the occasion of his 60th birthday. It was
supported by a grant of Deutsche Forschungs-
gemeinschaft (Lo 199/12-5). The improvement of
the English by M Ennis (PhD) and the technical
assistance of Traudl Acker and Evelyn Thursar is
greatly appreciated.
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